Understanding the Clinical Trial Process and Current Clinical Trials for Ocular Melanoma Patients

Dr. Kam Montazeri is an academic oncologist at Massachusetts General Hospital, where she specializes in the care of patients with melanoma, with particular academic interest in novel treatments for uveal melanoma patients. Dr. Montazeri is also an Instructor of Medicine at Harvard Medical School.  She has multiple publications in academic oncology, several ongoing translational projects in uveal melanoma, and currently leads several clinical trials as principal investigator at the Dana Farber Harvard Cancer Center, studying novel and immune-based therapies for patients with cutaneous and uveal melanoma. 

Dr. Eric Wehrenberg-Klee is an interventional radiologist at Massachusetts General Hospital in Boston, MA where he is the Director of the Center for Image-Guided Cancer Therapy, as well as an Assistant Professor of Radiology at Harvard Medical School.  He is the primary investigator on multiple investigator initiated and industry sponsored trials evaluating the role of minimally invasive interventional procedures for the treatment of cancer.  His laboratory work focus on the immune response to local tumor therapies and their synergy with checkpoint inhibition and is sponsored by grant funding from the National Cancer Institute.  

Andrea is a clinical research associate at Massachusetts General Hospital specializing in melanoma clinical trials. She’s been a part of over 15 melanoma studies and works closely with the trial sponsors and site physicians to enroll patients into trials and to confirm trial eligibility. She’s been at Mass General since 2021 and has a Bachelor’s degree in biomedical engineering from the City College of New York. 

Kristin has been living with ocular melanoma since February 2013. She was diagnosed with a “spot” on her liver in 2015, which was later found to be metastatic ocular melanoma. In 2019, she opted to participate in a clinical trial at the University of Pennsylvania that she participated in for 22 months.